Menu

Blog

Page 11738

Oct 20, 2015

BioViva and Telocyte « Michael Fossel

Posted by in categories: biotech/medical, ethics, life extension, neuroscience

Dr Michael Fossel comments on the recent Bioviva announcement of the first human gene therapy against aging.


The other day, a friend of mine, Liz Parrish, the CEO and founder of BioViva, made quite a splash when she injected herself with a viral vector containing genes for both telomerase and FST. Those in favor of what Liz did applaud her for her courage and her ability to move quickly and effectively in a landscape where red tape and regulatory concerns have – in the minds of some – impeded innovation and medical care. Those opposed to what Liz did have criticized her for moving too rapidly without sufficient concern for safety, ethics, or (from some critics) scientific rationale.

Many people have asked me to comment, both as an individual and as the founder of Telocyte. This occurs for two reasons. For one thing, I was the first person to ever advocate the use of telomerase as a clinical intervention, in discussions, in published journal articles, and in published books. My original JAMA articles (1997 and 1998), my first book on the topic (1996), and my textbook (2004) all clearly explained both the rational of and the implications for using telomerase as a therapeutic intervention to treat age-related disease. For another thing, Liz knew that our biotech firm, Telocyte, intends to do almost the same thing, but with a few crucial differences: we will only be using telomerase (hTERT) and we intend to pursue human trials that have FDA clearance, have full IRB agreement, and meet GMP (“Good Medical Production”) standards.

We cannot help but applaud Liz’s courage in using herself as a subject, a procedure with a long (and occasionally checkered) history in medical science. Using herself as the subject undercuts much of the ethical criticism that would be more pointed if she used other patients. Like many others, we also fully understand the urgent need for more effective therapeutic interventions: patients are not only suffering, but dying as we try to move ahead. In the case of Alzheimer’s disease, for example (our primary therapeutic target at Telocyte), there are NO currently effective therapies, a history of universal failure in human trials for experimental therapies, and an enormous population of patients who are currently losing their souls and their lives to this disease. A slow, measured approach to finding a cure is scarcely welcome in such a context.

Read more

Oct 20, 2015

Zumwalt-class Navy ship: Next-gen destroyer is a high-tech marvel (pictures)

Posted by in category: military

A truly amazing convergence of incredibly advanced technologies.


The US Navy has christened the first of three cutting-edge Zumwalt-class destroyers. But the next two may have weaponry straight out of science fiction.

Read Less.

Read more

Oct 20, 2015

2001: A Space Odyssey (1968)

Posted by in categories: entertainment, robotics/AI, space

The following dialoge from Arthur C. Clark’s classic explains genuine AI risk better than many academic papers:

Dave Bowman: Hello, HAL. Do you read me, HAL?
HAL: Affirmative, Dave. I read you.
Dave Bowman: Open the pod bay doors, HAL.
HAL: I’m sorry, Dave. I’m afraid I can’t do that.
Dave Bowman: What’s the problem?
HAL: I think you know what the problem is just as well as I do.
Dave Bowman: What are you talking about, HAL?
HAL: This mission is too important for me to allow you to jeopardize it.
Dave Bowman: I don’t know what you’re talking about, HAL.
HAL: I know that you and Frank were planning to disconnect me, and I’m afraid that’s something I cannot allow to happen.
Dave Bowman: [feigning ignorance] Where the hell did you get that idea, HAL?
HAL: Dave, although you took very thorough precautions in the pod against my hearing you, I could see your lips move.
Dave Bowman: Alright, HAL. I’ll go in through the emergency airlock.
HAL: Without your space helmet, Dave? You’re going to find that rather difficult.
Dave Bowman: HAL, I won’t argue with you anymore! Open the doors!
HAL: Dave, this conversation can serve no purpose anymore. Goodbye.


Quotes on IMDb: Memorable quotes and exchanges from movies, TV series and more…

Read more

Oct 20, 2015

GAO Reports: The Internet of Things — FAQs

Posted by in categories: futurism, internet, privacy, security, virtual reality, wearables

I think about pros and cons of living in a connected world … think about it …sometimes the answer it is not so simple, nor unique.

http://www.fas.org/sgp/crs/misc/R44227.pdf by Eric A. Fischer — Senior Specialist in Science and Technology, October 13, 2015

Oct 20, 2015

The Scientific Basis of Cryonics

Posted by in categories: cryonics, life extension

What the nervous system of the roundworm, frozen embryos, and extreme hypothermia tell us about preserving the mind.

Read more

Oct 20, 2015

U.S. Plans $6 Billion Investment in Space Situational Awareness

Posted by in categories: business, military, satellites, science, security, space, surveillance

http://spacenews.com/planned-u-s-investment-in-space-awarene…PqrOS.dpuf

Oct 20, 2015

U.S. Air Force Assigns Two Block Buy Launches

Posted by in categories: government, military, science, space, weapons

http://spacenews.com/u-s-air-force-assigns-two-block-buy-launches/

Oct 20, 2015

Drone ‘Angst’ extends beyond backyard spying

Posted by in categories: automation, counterterrorism, defense, disruptive technology, drones, ethics, military, privacy, surveillance

http://aviationweek.com/defense/drone-angst-extends-beyond-backyard-spying

Oct 20, 2015

Positron Dynamics plans to fly an antimatter powered cubsat

Posted by in category: space

In 2013, Positron Dynamics had seed funding from Paypal billionaire Peter Thiel’s Breakout Labs. Initial simulations show that as much as 10 micrograms of positrons could be produced each week with a linear accelerator,” says co-founder Ryan Weed, PhD, a physicist and former cryogenic engineer for Jeff Bezos’s space flight company Blue Origin.

Now they have stated in a new presentation that they will have an antimatter powered cubesat vehicles in 2016–2019. They will be able to keep a cubesat in low earth orbit for seven years instead of few days. Then they will enable high speed spacecraft to go the outer solar system and then to the stars at a significant fraction of the speed of light.

Read more

Oct 19, 2015

SpaceX Changes Its Falcon 9 Rocket Return-to-Flight Plans — By Peter B. de Selding | SPACE.com

Posted by in categories: business, Elon Musk, satellites

orbcomm-falcon-9-hanger

“SpaceX on Oct. 16 said it had changed its Falcon 9 return-to-flight plans and would first launch 11 small Orbcomm messaging satellites into low Earth orbit, and then test reignition of the rocket’s redesigned second-stage engine during the same flight before launching SES’s heavier telecommunications satellite into higher orbit, a mission that will need the reignition capability

Read more